Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 0.3% – What’s Next?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)’s stock price dropped 0.3% on Tuesday . The company traded as low as $1.44 and last traded at $1.48. Approximately 34,880 shares were traded during trading, a decline of 15% from the average daily volume of 40,838 shares. The stock had previously closed at $1.4850.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Cyclerion Therapeutics Trading Up 3.4%

The company’s 50-day moving average is $1.38 and its 200-day moving average is $1.74. The firm has a market cap of $5.93 million, a price-to-earnings ratio of -2.01 and a beta of 0.94.

Hedge Funds Weigh In On Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new position in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned about 0.40% of Cyclerion Therapeutics at the end of the most recent reporting period. 75.62% of the stock is currently owned by institutional investors and hedge funds.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.